RATe Control in Atrial Fibrillation

Rate Control in Atrial Fibrillation

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00313157

Acronym

RATAF

Enrollment

Registered

2006-04-12

Start date

2006-04-30

Completion date

2010-09-30

Last updated

2014-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation

Brief summary

The purpose of this study is to compare the effect of metoprolol, verapamil, diltiazem and carvedilol on ventricular rate, working capacity and quality of life in patients with chronic atrial fibrillation.

Detailed description

This is a randomised, single blinded, cross-over study comparing the efficacy of metoprolol 100 mg o.d., verapamil 240 mg o.d., diltiazem 360 mg o.d. and carvedilol 25 mg o.d. in reducing ventricular rate in atrial fibrillation. A total of 60 patients will be included, with a minimum of 20 women.Patients will receive each of the drug regimens in a random sequence. Each regimen will be administered for 3 weeks, ensuring that steady-state drug concentration will be attained and to provide an adequate washout of the previous treatment. Following each regimen, exercise ECG and Holter registration will be performed and patients will undergo laboratory evaluation and complete QoL-forms. They will then be started on the next randomly assigned treatment regimen, until the entire sequence of treatment schedules is completed.

Interventions

DRUGMetoprolol

DRUGDiltiazem

DRUGVerapamil

DRUGCarvedilol

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Persistent or permanent atrial fibrillation with ventricular rate \> 80/min at rest and/or \> 100/min average at daytime. * Male or female, age \> 18.

Exclusion criteria

* Hypersensitivity or contraindication to metoprolol, verapamil, diltiazem or carvedilol. * Coronary heart disease or heart failure * Systolic blood pressure \< 100 mmHg * AV-conduction disturbance * Severe hepatic or renal dysfunction * Thyrotoxicosis * Ongoing treatment with Digitalis * Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame	Description
Ventricular rate	Three weeks	Ventricular rate evaluated after three weeks on study drug treatment

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026